Cargando…

S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model

The mucolytic agent S-carboxymethylcysteine is widely used as an expectorant for the treatment of numerous respiratory disorders. The metabolic fate of S-carboxymethyl-L-cysteine is complex. Several clinical studies have demonstrated that the metabolism of this agent differs within the same individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Catanesi, Mariano, Brandolini, Laura, d’Angelo, Michele, Tupone, Maria Grazia, Benedetti, Elisabetta, Alfonsetti, Margherita, Quintiliani, Massimiliano, Fratelli, Maddalena, Iaconis, Daniela, Cimini, Annamaria, Castelli, Vanessa, Allegretti, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533464/
https://www.ncbi.nlm.nih.gov/pubmed/34680584
http://dx.doi.org/10.3390/biomedicines9101467
_version_ 1784587319068590080
author Catanesi, Mariano
Brandolini, Laura
d’Angelo, Michele
Tupone, Maria Grazia
Benedetti, Elisabetta
Alfonsetti, Margherita
Quintiliani, Massimiliano
Fratelli, Maddalena
Iaconis, Daniela
Cimini, Annamaria
Castelli, Vanessa
Allegretti, Marcello
author_facet Catanesi, Mariano
Brandolini, Laura
d’Angelo, Michele
Tupone, Maria Grazia
Benedetti, Elisabetta
Alfonsetti, Margherita
Quintiliani, Massimiliano
Fratelli, Maddalena
Iaconis, Daniela
Cimini, Annamaria
Castelli, Vanessa
Allegretti, Marcello
author_sort Catanesi, Mariano
collection PubMed
description The mucolytic agent S-carboxymethylcysteine is widely used as an expectorant for the treatment of numerous respiratory disorders. The metabolic fate of S-carboxymethyl-L-cysteine is complex. Several clinical studies have demonstrated that the metabolism of this agent differs within the same individual, with sulfur oxygenated metabolites generated upon night-time administration. It has been indicated that this drug behaves like a free radical scavenger and that, in this regard, the sulfide is the active species with sulphoxide metabolites (already oxidized) being inactive. Consequently, a night-time consumption of the drug should be more effective upon daytime administration. Still, this diurnal variation in biotransformation (deactivation) is dependent on the genetic polymorphism on which relies the patient population capacities of S-carboxymethyl-L-cysteine sulphoxidation. It has been reported that those cohorts who are efficient sulfur oxidizers will generate inactive oxygenated metabolites. In contrast, those who have a relative deficiency in this mechanism will be subjected to the active sulfide for a more extended period. In this regard, it is noteworthy that 38–39% of Parkinson’s disease patients belong to the poor sulphoxide cohort, being exposed to higher levels of active sulfide, the active antioxidant metabolite of S-carboxymethyl-L-cysteine. Parkinson’s disease is a neurodegenerative disorder that affects predominately dopaminergic neurons. It has been demonstrated that oxidative stress and mitochondrial dysfunction play a crucial role in the degeneration of dopaminergic neurons. Based on this evidence, in this study, we evaluated the effects of S-carboxymethyl cysteine in an in vitro model of Parkinson’s disease in protecting against oxidative stress injury. The data obtained suggested that an S-carboxymethylcysteine-enriched diet could be beneficial during aging to protect neurons from oxidative imbalance and mitochondrial dysfunction, thus preventing the progression of neurodegenerative processes.
format Online
Article
Text
id pubmed-8533464
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85334642021-10-23 S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model Catanesi, Mariano Brandolini, Laura d’Angelo, Michele Tupone, Maria Grazia Benedetti, Elisabetta Alfonsetti, Margherita Quintiliani, Massimiliano Fratelli, Maddalena Iaconis, Daniela Cimini, Annamaria Castelli, Vanessa Allegretti, Marcello Biomedicines Article The mucolytic agent S-carboxymethylcysteine is widely used as an expectorant for the treatment of numerous respiratory disorders. The metabolic fate of S-carboxymethyl-L-cysteine is complex. Several clinical studies have demonstrated that the metabolism of this agent differs within the same individual, with sulfur oxygenated metabolites generated upon night-time administration. It has been indicated that this drug behaves like a free radical scavenger and that, in this regard, the sulfide is the active species with sulphoxide metabolites (already oxidized) being inactive. Consequently, a night-time consumption of the drug should be more effective upon daytime administration. Still, this diurnal variation in biotransformation (deactivation) is dependent on the genetic polymorphism on which relies the patient population capacities of S-carboxymethyl-L-cysteine sulphoxidation. It has been reported that those cohorts who are efficient sulfur oxidizers will generate inactive oxygenated metabolites. In contrast, those who have a relative deficiency in this mechanism will be subjected to the active sulfide for a more extended period. In this regard, it is noteworthy that 38–39% of Parkinson’s disease patients belong to the poor sulphoxide cohort, being exposed to higher levels of active sulfide, the active antioxidant metabolite of S-carboxymethyl-L-cysteine. Parkinson’s disease is a neurodegenerative disorder that affects predominately dopaminergic neurons. It has been demonstrated that oxidative stress and mitochondrial dysfunction play a crucial role in the degeneration of dopaminergic neurons. Based on this evidence, in this study, we evaluated the effects of S-carboxymethyl cysteine in an in vitro model of Parkinson’s disease in protecting against oxidative stress injury. The data obtained suggested that an S-carboxymethylcysteine-enriched diet could be beneficial during aging to protect neurons from oxidative imbalance and mitochondrial dysfunction, thus preventing the progression of neurodegenerative processes. MDPI 2021-10-14 /pmc/articles/PMC8533464/ /pubmed/34680584 http://dx.doi.org/10.3390/biomedicines9101467 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Catanesi, Mariano
Brandolini, Laura
d’Angelo, Michele
Tupone, Maria Grazia
Benedetti, Elisabetta
Alfonsetti, Margherita
Quintiliani, Massimiliano
Fratelli, Maddalena
Iaconis, Daniela
Cimini, Annamaria
Castelli, Vanessa
Allegretti, Marcello
S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model
title S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model
title_full S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model
title_fullStr S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model
title_full_unstemmed S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model
title_short S-Carboxymethyl Cysteine Protects against Oxidative Stress and Mitochondrial Impairment in a Parkinson’s Disease In Vitro Model
title_sort s-carboxymethyl cysteine protects against oxidative stress and mitochondrial impairment in a parkinson’s disease in vitro model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533464/
https://www.ncbi.nlm.nih.gov/pubmed/34680584
http://dx.doi.org/10.3390/biomedicines9101467
work_keys_str_mv AT catanesimariano scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT brandolinilaura scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT dangelomichele scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT tuponemariagrazia scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT benedettielisabetta scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT alfonsettimargherita scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT quintilianimassimiliano scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT fratellimaddalena scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT iaconisdaniela scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT ciminiannamaria scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT castellivanessa scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel
AT allegrettimarcello scarboxymethylcysteineprotectsagainstoxidativestressandmitochondrialimpairmentinaparkinsonsdiseaseinvitromodel